Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
8th FENS Forum of Neuroscience
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Company restores access to multiple sclerosis drug after pressure from neurologists.
Remyelination therapy goes to trial for multiple sclerosis
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Epigenetic changes in patients with multiple sclerosis.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Pediatric multiple sclerosis.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Assessment of statistical significance and clinical relevance.

Pages